Journal of Hematology & Oncology (Nov 2022)

Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC

  • Ludovic Jondreville,
  • Maud D’Aveni,
  • Hélène Labussière-Wallet,
  • Amandine Le Bourgeois,
  • Alban Villate,
  • Ana Berceanu,
  • Silvia-Maria Bezsera,
  • Anne Thiebaut,
  • Marion Boissard-Simonet,
  • Marlène Legrand,
  • Jérôme Cornillon,
  • Marie-Thérèse Rubio,
  • Patrice Chevallier,
  • Stéphanie Nguyen

DOI
https://doi.org/10.1186/s13045-022-01387-0
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Since the emergence of the Omicron variant of SARS-CoV-2, though considered less virulent, hospitalization and death rates among immunocompromised patients remain high, especially for poor responders to vaccination. We conducted a retrospective multicentric study to evaluate pre-exposure prophylaxis with AZD7442 (tixagevimab/cilgavimab) for preventing COVID-19 in adult allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. Among the 161 patients of our cohort, 22 (14%) contracted COVID-19 after a median follow-up of 105 days, but no severe form was observed. Only one major adverse event was reported: an acute coronary syndrome, resolved without sequelae. Pending randomized controlled trial results, our data support the use of AZD7442 as pre-exposure prophylaxis for COVID-19 during Omicron wave in allo-HSCT patients who failed to develop humoral immunity to vaccination, to prevent severe and potentially lethal forms of SARS-CoV-2 infection.

Keywords